NASDAQ: WGS · Industrial Applications and Services · 3 alerts · CIK 1818331
Share price
$51.02Close, Nov 16
Market cap
$1.53B
Shares outstanding
29.97MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Services-Health ServicesSIC 8000
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All GeneDx Holdings Corp. filings on SEC EDGAR ↗
For the nine months ended September 30, 2026, GeneDx reported total revenue of $339.8 million, an 11% increase year-over-year, though net loss widened significantly to $93.4 million due to a $31.3 million impairment loss and increased SG&A expenses. The company strengthened its balance sheet by securing $146.0 million in long-term debt proceeds while repaying its previous Perceptive debt facility.
GeneDx reported Q3 2026 revenue of $123.1 million, driven by 25% year-over-year growth in exome and genome test volume. The company achieved adjusted net income of $8.6 million and expanded its adjusted gross margin to 72%. Management reaffirmed full-year 2026 revenue guidance of $475 million to $490 million.
Term
Q3 2026
“Our Q3 results reflect profitable execution in a growing market, as we translate the rising demand for exome and genome testing into durable revenue growth. Our priorities are clear: improve the economics of our testing, expand utilization, and deliver leading products at scale. By uniting these priorities with our clinical expertise and differentiated exome and genome capabilities, we are bringing life-changing answers to more families.”
GeneDx Holdings CEO Katherine Stueland Sells $1.03M of Stock
Katherine Stueland, CEO, sold 10,501 shares of GeneDx Holdings Corp. at $94.26 to $99.00 a share (average $97.61) in 5 transactions, worth $1.03M in total on Sep 16, 2026. Shares held after the trade: 115,476 (-2.6%).